Page last updated: 2024-10-30

leflunomide and Cardiac Hypertrophy

leflunomide has been researched along with Cardiac Hypertrophy in 1 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pescatore, LA1
Laurindo, FRM1

Other Studies

1 other study available for leflunomide and Cardiac Hypertrophy

ArticleYear
Leflunomide counter
    Clinical science (London, England : 1979), 2018, 05-31, Volume: 132, Issue:10

    Topics: Angiotensin II; Aniline Compounds; Animals; Cardiomegaly; Crotonates; Fibrosis; Hydroxybutyrates; Le

2018